Efficacy and safety of pasireotide treatment in acromegaly: A systematic review and single arm meta-analysis
Authors' conclusion
Pasireotide demonstrates biochemical control in patients with active or uncontrolled acromegaly. Although a high rate of hyperglycemic adverse events and diabetes mellitus related to the treatment were observed, most of them were manageable.
Study context
- Population
- Patients with active or uncontrolled acromegaly; 82.2% inadequately controlled
- Participants
- 590 patients9 studies
- Outcome
- Biochemical control
- Follow-up
- 12 months
Methodological detailsclinical trials and observational cohorts
- Clinical trials and observational cohorts
Pooled result
As reported in the abstract
Pooled biochemical control rate
Pooled biochemical control rate after pasireotide
26.50%
95% CI 14.87–42.66
Further pooled results
Normalized IGF-1
- Prevalence of normalized IGF-1
- 36.27% (95% CI 29.15-43.39)
Low GH levels
- Prevalence of low GH levels
- 34.76% (95% CI 24.58-44.95)
Biochemical control in extension phase
- Prevalence of biochemical control, 4 studies with extension phase results
- 29.03% (95% CI 11.49-46.58)
- Events / patients
- 76 out of 281
- Biochemical response rates were sustained throughout the extension phase
Safety
Gastrointestinal disturbances
- Gastrointestinal disturbances, % of patients
- 31.26% (95% CI 7.44-72.01)
- Most commonly reported adverse events
Hyperglycemia
- Hyperglycemia, % of patients
- 29.55% (95% CI 21.80-37.29)
- Most commonly reported adverse events
New-onset DM
- Incidence of new-onset DM after pasireotide, significantly increased
- 23.36% (95% CI 19.58-27.13)
Original publication
Efficacy and safety of pasireotide treatment in acromegaly: A systematic review and single arm meta-analysis. Pituitary. Published 1 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →